Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Taro Pharmaceutical Industries	OPKO Health	Corcept Therapeutics	Viela Bio	Organogenesis
Symbol	NYSE:TARO	NASDAQ:OPK	NASDAQ:CORT	NASDAQ:VIE	NASDAQ:ORGO
Price Information
Current Price	$72.18	$3.42	$20.45	$53.01	$17.92
52 Week Range	Buy	Buy	Buy	Hold	Buy
MarketRank™
Overall Score	1.1	1.9	1.8	0.8	1.0
Analysis Score	2.5	3.5	2.3	1.1	1.5
Community Score	2.2	2.5	2.7	1.2	2.7
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	1.7	1.7	0.8	0.8
Earnings & Valuation Score	0.6	1.9	2.5	0.6	0.0
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Hold	Buy
Consensus Price Target	$81.00	$9.00	$24.00	$57.00	$17.50
% Upside from Price Target	12.22% upside	163.16% upside	17.36% upside	7.53% upside	-2.34% downside
Trade Information
Market Cap	$2.76 billion	$2.29 billion	$2.39 billion	$2.91 billion	$2.30 billion
Beta	0.92	1.98	1.04	0.43	1.84
Average Volume	28,560	6,818,914	569,850	1,065,058	827,913
Sales & Book Value
Annual Revenue	$644.77 million	$901.90 million	$306.49 million	$50 million	$260.98 million
Price / Sales	4.28	2.54	7.78	58.26	8.80
Cashflow	$6.51 per share	N/A	$0.61 per share	N/A	N/A
Price / Cash	11.09	N/A	33.26	N/A	N/A
Book Value	$55.15 per share	$2.43 per share	$3.25 per share	$7.14 per share	$0.59 per share
Price / Book	1.31	1.41	6.29	7.42	30.37
Profitability
Net Income	$244.24 million	$-314,920,000.00	$94.18 million	$-86,430,000.00	$-40,450,000.00
EPS	$6.35	($0.41)	$0.77	($7.02)	($0.42)
Trailing P/E Ratio	N/A	N/A	22.98	N/A	N/A
Forward P/E Ratio	17.23	57.00	22.23	N/A	N/A
P/E Growth	N/A	5.84	N/A	N/A	N/A
Net Margins	-45.94%	-9.79%	30.73%	N/A	-1.61%
Return on Equity (ROE)	10.36%	-2.61%	25.38%	-33.97%	-10.03%
Return on Assets (ROA)	8.38%	-1.80%	23.16%	-31.49%	-2.22%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	0.13%	N/A	N/A	1.54%
Current Ratio	2.53%	1.27%	10.77%	19.51%	1.95%
Quick Ratio	2.25%	0.94%	10.65%	19.49%	1.50%
Ownership Information
Institutional Ownership Percentage	11.23%	28.51%	75.44%	46.98%	4.62%
Insider Ownership Percentage	13.80%	40.90%	16.40%	31.50%	57.20%
Miscellaneous
Employees	1,464	5,269	236	166	910
Shares Outstanding	38.26 million	670.16 million	116.63 million	54.95 million	128.21 million
Next Earnings Date	5/18/2021 (Estimated)	7/29/2021 (Estimated)	8/3/2021 (Estimated)	5/12/2021 (Estimated)	8/9/2021 (Estimated)
Optionable	Optionable	Optionable	Optionable	Not Optionable	Not Optionable

Source	Headline
	Organogenesis Holdings Inc. (ORGO) CEO Gary Gillheeney on Q1 2021 Results - Earnings Call Transcript - Seeking Alpha seekingalpha.com - May 11 at 7:11 PM
	Organogenesis Holdings Inc (ORGO) Q1 2021 Earnings Call Transcript - Motley Fool fool.com - May 11 at 7:11 PM
	Where Does Organogenesis Holdings Inc (ORGO) Stock Fall in the Drug Manufacturers - Specialty & Generic Field After It Has Fallen -14.71% This Week? - InvestorsObserver investorsobserver.com - May 11 at 2:10 PM
	Form 10-Q Organogenesis Holdings For: Mar 31 - StreetInsider.com streetinsider.com - May 11 at 2:10 PM
	Organogenesis (NASDAQ:ORGO) Shares Down 6.8% After Analyst Downgrade americanbankingnews.com - May 11 at 12:27 PM
	Organogenesis (NASDAQ:ORGO) Given New $26.00 Price Target at SVB Leerink americanbankingnews.com - May 11 at 11:18 AM
	CORRECTING and REPLACING – Organogenesis Holdings Inc. Reports First Quarter 2021 Financial Results - Yahoo Finance finance.yahoo.com - May 11 at 9:10 AM
	Organogenesis Holdings Inc (ORGO) Q1 2021 Earnings Call Transcript finance.yahoo.com - May 11 at 9:10 AM
	Organogenesis (ORGO) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance finance.yahoo.com - May 11 at 1:36 AM
	Organogenesis Holdings Posts Q1 EPS Of $0.07 - CMLViz.com - CML News cmlviz.com - May 10 at 8:35 PM
	Organogenesis (ORGO) Surpasses Q1 Earnings and Revenue Estimates - Nasdaq nasdaq.com - May 10 at 8:35 PM
	Organogenesis Holdings: Q1 Earnings Insights - Benzinga benzinga.com - May 10 at 8:35 PM
	Organogenesis: Q1 Earnings Snapshot - San Francisco Chronicle sfchronicle.com - May 10 at 8:35 PM
	CORRECTING and REPLACING – Organogenesis Holdings Inc. - GlobeNewswire globenewswire.com - May 10 at 8:35 PM
	Organogenesis Holdings Inc. Reports First Quarter 2021 Financial Results finance.yahoo.com - May 10 at 8:35 PM
	CORRECTING and REPLACING – Organogenesis Holdings Inc. Reports First Quarter 2021 Financial Results finance.yahoo.com - May 10 at 8:35 PM
	Organogenesis (ORGO) Surpasses Q1 Earnings and Revenue Estimates finance.yahoo.com - May 10 at 8:35 PM
	Organogenesis (NASDAQ:ORGO) Updates FY 2021 Earnings Guidance americanbankingnews.com - May 10 at 5:22 PM
	Diabetic Foot Ulcer Therapeutic Market : Information, Figures And Analytical Insights 2021-2026-B. Braun Melsungen AG, Smith & Nephew, Inc., Organogenesis, Inc. – The Shotcaller - The Shotcaller theshotcaller.net - May 10 at 10:35 AM
	Organogenesis Appoints Jon Giacomin to Board of Directors - GlobeNewswire globenewswire.com - May 10 at 10:35 AM
	Organogenesis Showcases Latest Advanced Wound Care - GlobeNewswire globenewswire.com - May 8 at 8:50 AM
	Zacks Investment Research Lowers Organogenesis (NASDAQ:ORGO) to Hold marketbeat.com - May 8 at 2:26 AM
	Earnings Outlook for Organogenesis Holdings - Benzinga benzinga.com - May 7 at 1:02 PM
	Organogenesis Showcases Latest Advanced Wound Care Innovations and Research at SAWC Spring \| WHS 2021 Virtual Meeting - Yahoo Finance finance.yahoo.com - May 6 at 10:01 PM
	Organogenesis Showcases Latest Advanced Wound Care Innovations and Research at SAWC Spring \| WHS 2021 Virtual Meeting finance.yahoo.com - May 6 at 10:01 PM
	05:00 ET 2020 STELLARIS Award Recipient Announced - PRNewswire prnewswire.com - May 6 at 7:00 AM
	Zacks Investment Research Downgrades Organogenesis (NASDAQ:ORGO) to Hold marketbeat.com - April 17 at 3:20 AM

Date	Company	Brokerage	Action
2/1/2021	Taro Pharmaceutical Industries	HC Wainwright	Boost Price Target
2/19/2021	OPKO Health	Barrington Research	Boost Price Target
7/31/2020	OPKO Health	Piper Sandler	Boost Price Target
11/25/2019	OPKO Health	Piper Jaffray Companies	Initiated Coverage
8/7/2018	OPKO Health	Cantor Fitzgerald	Reiterated Rating
8/5/2020	Corcept Therapeutics	Jefferies Financial Group	Downgrade
2/5/2019	Corcept Therapeutics	B. Riley	Set Price Target
8/10/2018	Corcept Therapeutics	Stifel Nicolaus	Reiterated Rating
2/8/2021	Viela Bio	Guggenheim	Downgrade
2/8/2021	Viela Bio	Wedbush	Downgrade
7/15/2020	Viela Bio	The Goldman Sachs Group	Upgrade
6/3/2020	Viela Bio	Cowen	Reiterated Rating
5/14/2020	Viela Bio	Morgan Stanley	Boost Price Target
5/11/2021	Organogenesis	SVB Leerink	Lower Price Target
3/12/2021	Organogenesis	Credit Suisse Group	Boost Price Target
1/14/2021	Organogenesis	BTIG Research	Boost Price Target
9/21/2020	Organogenesis	Oppenheimer	Reiterated Rating

(Data available from 5/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources